Why is it essential for specific other uses of Alpha1 Antitrypsin to be recognized and become viable?
To accelerate additional research into Alpha1 Antitrypsin, its deficiency, and all the other conditions and diseases that are or could be associated with lower than acceptable levels of Alpha1 Antitrypsin within the human body of individuals requiring more Alpha1 Antitrypsin that we have identified in these pages.
These findings will cause an increase in the demand and then production of Alpha1 Antitrypsin. When this production occurs, additional uses of Alpha1 Antitrypsin products will be made available to every individual in need of this valuable protein! Doing so will also bring other producers into the marketplace, therefore more companies producing the Alpha1 Antitrypsin.
By having a greater demand and need for Alpha1 Antitrypsin products for multiple disease prevention and treatments and uses, the cost can be driven down by the free market system around the world.
By reducing the cost of the product, medical panels would and should have less reluctance in approving more individuals that should be approved for infusion therapy and other types of utilizing the Alpha1 Antitrypsin protein for human consumption and use. For instance, starting patients with higher FEV 1 breathing test and MZ's to start Alpha1 Antitrypsin therapy before they develop emphysema and COPD and before the loss of the valuable function of the lungs, other vital organs, and many other conditions listed in Mark Egly's patent regarding “METHOD OF PREVENTING AND/OR TREATING A PLURALITY OF DISEASES,”
Having physicians of all specialties increase their knowledge and awareness that Alpha1 Antitrypsin can be helpful in their specialty, as we have described in unitingdoctors.com
With physicians gaining knowledge of additional uses of Alpha1 Antitrypsin Deficiency protein products, this may lead to more use and potentially lifesaving capabilities for more medical specialist areas than now exist. This awareness will lead to better capabilities for patient care with their awareness and breaking paradigms. Then they may see that Alpha1 Antitrypsin products' benefits go well beyond disease that pertains only to lung and liver issues. It is an absolute must in changing previous paradigms with Alpha1 Antitrypsin Deficiency. With physicians becoming aware that other uses have been found, more production of this very expensive treatment style would lead to lower production costs.
By having a greater awareness that phenotype alone testing is shortsighted when Alpha1 Antitrypsin levels are a much greater and significant factor in potential disease detection, treatment, and avoidance of potential manifestation of other medical conditions!
We are here to assist the realization that anyone with lower than average circulating Alpha1 Antitrypsin levels in their systems will cause individuals and medical professionals to further research previously unrelated diseases today that, in reality, have potentially related conditions and diseases that are coexisting and have a comorbidity relationship to lower levels of Alpha1 Antitrypsin in the body, and will bring more physicians into the knowledge of how widespread genetic and non-genetic Alpha1 Antitrypsin Deficiency and lower levels of Alpha1 Antitrypsin products is!
We are here to assist individuals and the medical community, not currently having the communication of specialists from different areas of medical expertise working together to test, recognize and make proper correlations and diagnose the diseases!
We are here to assist the medical community not currently having the communication of specialists from different areas of medical expertise communicating and working together to work with experts properly and jointly outside the scope of their specific areas of expertise!!!!!!!!
We are here to assist and make everyone aware that if in the lungs or any other area of the body where an excessive amount of neutrophil elastase exists that is not properly neutralized by Alpha1 Antitrypsin protease inhibition, this would potentially develop or metastasize conditions within the body! An example is excessive white blood cells in the lungs.
Our disease is rarely found, but it is borderline rampant in some sectors of the world. The reason it has been found so rarely is that physicians only find the easy cases, those where the patient is suffering from severe liver disease, COPD, emphysema in the world of smokers, heavy alcohol consumption, and drug abuse. We are bringing many more tools to identify diseases never associated with Alpha1 Antitrypsin Deficiency before!